Anacetrapib vs Placebo Anacetrapib: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0737 | 0.0697 | 0.078 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.0759 | 0.0718 | 0.0802 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | -0.00217 | -0.00809 | 0.00374 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 0.971 | 0.898 | 1.05 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 0.969 | 0.89 | 1.06 | log | ClinicalTrials.gov | |
| Number needed to treat, for one fewer death from any cause on Anacetrapib than on Placebo Anacetrapib | 460 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Anacetrapib | anacetrapib: tablet, 100mg daily | 1,122 | 15,225 | EG000 | ClinicalTrials.gov |
| Group 2 | Placebo Anacetrapib | placebo anacetrapib: tablet, 1 tablet daily | 1,155 | 15,224 | EG001 | ClinicalTrials.gov |
Harm 2
| Field | Value | Source |
|---|---|---|
| What it counts | Total, all-cause mortality | ClinicalTrials.gov |
| Time frame | Randomized treatment phase during median follow-up period of 4.1years | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification | ClinicalTrials.gov |
| NCT number | NCT01252953 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Atherosclerotic Cardiovascular Disease | ClinicalTrials.gov |
| Interventions | Anacetrapib, Placebo anacetrapib | ClinicalTrials.gov |
| Lead sponsor | University of Oxford | ClinicalTrials.gov |
| Results first posted | 2018-05-04 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT01252953?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.